↑ 薬物リストへ　← 戻る

Meglumine    (DrugBank: Meglumine)

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
28全身性アミロイドーシス4
53シェーグレン症候群1

28. 全身性アミロイドーシス　［臨床試験数：212，薬物数：234（DrugBank：72），標的遺伝子数：54，標的パスウェイ数：170］
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 212 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-JapicCTI-111678
07/11/201102/11/2011The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M TransthyretinThe Effect Of Transthyretin Stabilization, Safety, Tolerability, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin: A Phase 3, Open-Label(B3461010) Transthyretin Familial Amyloid PolyneuropathyIntervention name : tafamidis meglumine
INN of the intervention : tafamidis meglumine
Dosage And administration of the intervention : 20 mg QD
Control intervention name : null		Pfizer Japan Inc.NULL2075BOTH10Phase 3NULL
2EUCTR2009-011535-12-PT
(EUCTR)		09/09/200915/07/2009Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin AmyloidosisOpen-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis Transthyretin Amyloidosis (ATTR)
MedDRA version: 14.1;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]		Product Name: Tafamidis meglumine
Product Code: Fx-1006A
INN or Proposed INN: tafamidis
Other descriptive name: [d-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)]		Pfizer Inc.NULLNot RecruitingFemale: yes
Male: yes		110France;United States;Portugal;Argentina;Brazil;Germany;Italy;Sweden
3EUCTR2009-011535-12-DE
(EUCTR)		26/08/200918/05/2009In preparationOpen-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis Transthyretin Amyloidosis (ATTR)
MedDRA version: 14.1;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]		Product Name: Tafamidis meglumine
Product Code: Fx-1006A
INN or Proposed INN: tafamidis
Other descriptive name: [d-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)]		Pfizer Inc.NULLNot RecruitingFemale: yes
Male: yes		110Portugal;Germany;Argentina;France;Italy;United States;Sweden;Brazil
4EUCTR2009-011535-12-SE
(EUCTR)		24/06/200910/06/2009To obtain additional long-term, safety and efficacy data for tafamidis in subjects with transthyretin (TTR) familial amyloid polyneuropathy (TTR-FAP) and to continue to provide the Tafamidis to subjects with TTR-FAP who have completed Protocol Fx-006 or Protocol Fx1A-201Open-Label Safety and Efficacy Evaluation of Fx-1006A in Subjects with Transthyretin (TTR) Amyloidosis Transthyretin Amyloidosis (ATTR)
MedDRA version: 16.1;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]		Trade Name: Vyndaqel 20mg soft capsule
Product Name: Tafamidis Meglumine 20mg Soft Gelatin Capsule (Clinical trial image)
Product Code: PF-06291826-83/Fx-1006A
INN or Proposed INN: Tafamidis meglumine
Other descriptive name: tafamidis meglumine 20 mg soft gelatin capsules
Trade Name: Vyndaqel 20mg soft capsule
Product Name: Tafamidis Meglumine 20mg Soft Gelatin Capsule (Commerical image)
Product Code: PF-06291826-83/Fx-1006A
INN or Proposed INN: Tafamidis meglumine
Other descriptive name: tafamidis meglumine 20 mg soft gelatin capsules		Pfizer Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		110Portugal;France;United States;Argentina;Brazil;Germany;Italy;Sweden

53. シェーグレン症候群　［臨床試験数：234，薬物数：270（DrugBank：85），標的遺伝子数：49，標的パスウェイ数：174］
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02899377
(ClinicalTrials.gov)		November 18, 201623/8/2016A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS PtsA Pilot Study to Evaluate Molecular Imaging Methods in Primary Sjögren's SyndromeAutoimmune DiseasesRadiation: 18F-FDG PET/CT Imaging;Radiation: 11C-MET PET/CT Imaging;Procedure: MRI Imaging with intravenous contrast with gadoterate meglumine;Procedure: Minor Salivary gland (labial) biopsyGlaxoSmithKlineQuintiles, Inc.Completed30 YearsN/AAll25N/AUnited Kingdom

先頭へ